Solesence, Inc. is scheduled to report its Q2 2026 financial results on August 19, 2026, though no formal Wall Street consensus revenue or EPS estimates exist due to a current lack of analyst coverage for the micro-cap stock. The primary focus for investors is the company’s ability to achieve its management-targeted 30% gross margin floor, a key objective of its ongoing "Transform & Transcend" strategic initiative.
Management recently rescheduled the earnings call from its original August 11 date to finalize financial reviews following a reported inventory costing error that delayed its 10-Q filing. This follows a challenging Q1 2026 where revenue fell 11% year-over-year to $13.0 million, and shareholders are now looking for signs of operational recovery through new product commercialization in the hair and scalp care segments.